Literature DB >> 11253130

The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A).

K S Clarkson1, I C Sturdgess, A J Molyneux.   

Abstract

AIM: To compare the sensitivity and staining pattern of the new immunohistochemical antibody to tyrosinase (T311) with S-100, HMB45, and the recently evaluated antibody to melan-A (A103) in a range of melanocytic lesions.
METHOD: Archival, formalin fixed, paraffin wax embedded sections from 50 benign and malignant melanocytic lesions were stained immunohistochemically with anti-tyrosinase, A103, S-100, and HMB45. They were scored semiquantitatively for the distribution and intensity of staining.
RESULTS: All melanomas, with the exception of desmoplastic melanoma, showed some staining with all four antibodies. Overall, T311 and A103 showed an intermediate sensitivity compared with that of S-100 and HMB45. T311 stained most benign and malignant lesions strongly and diffusely with minimal background staining. Immunoreactivity was found to be patchy in some naevi, with weak or absent staining of the mature melanocytes. A103 showed strong and diffuse staining of all benign lesions and most melanomas with minimal background staining. S-100 was the most sensitive, with diffuse staining of most lesions, including desmoplastic and metastatic melanoma, but lacked specificity. HMB45 was the least sensitive antibody, frequently demonstrating patchy staining with absent staining in some benign naevi.
CONCLUSIONS: S-100 remains the most sensitive marker of melanocytes. However, because of its lack of specificity, it should be used with at least one other more specific antibody. HMB45 is more specific, but lacks sensitivity; T311 is a reliable marker of melanocytes in paraffin wax embedded sections and is worth consideration for use in a staining panel, although it shows no additional benefit over A103.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11253130      PMCID: PMC1731371          DOI: 10.1136/jcp.54.3.196

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  21 in total

1.  Reactivity of HMB-45 monoclonal antibody with sweat-gland tumours of the skin.

Authors:  J Kanitakis; C Hermier; B Chouvet; J Thivolet
Journal:  Acta Derm Venereol       Date:  1991       Impact factor: 4.437

2.  Melanocyte lineage-specific antigens recognized by monoclonal antibodies NKI-beteb, HMB-50, and HMB-45 are encoded by a single cDNA.

Authors:  G J Adema; A J de Boer; R van 't Hullenaar; M Denijn; D J Ruiter; A M Vogel; C G Figdor
Journal:  Am J Pathol       Date:  1993-12       Impact factor: 4.307

3.  HMB-45 staining in benign and malignant melanocytic lesions. A reflection of cellular activation.

Authors:  H G Skelton; K J Smith; T L Barrett; G P Lupton; J H Graham
Journal:  Am J Dermatopathol       Date:  1991-12       Impact factor: 1.533

4.  Nevus cell maturation or atrophy?

Authors:  G Goovaerts; N Buyssens
Journal:  Am J Dermatopathol       Date:  1988-02       Impact factor: 1.533

Review 5.  Immunohistochemistry in the evaluation of melanocytic tumors.

Authors:  D J Ruiter; E B Bröcker
Journal:  Semin Diagn Pathol       Date:  1993-02       Impact factor: 3.464

6.  HMB-45 recognizes stimulated melanocytes.

Authors:  B R Smoller; N S McNutt; A Hsu
Journal:  J Cutan Pathol       Date:  1989-04       Impact factor: 1.587

7.  Immunohistochemical study on the distribution of alpha and beta subunits of S-100 protein in human neoplasm and normal tissues.

Authors:  K Takahashi; T Isobe; Y Ohtsuki; T Akagi; H Sonobe; T Okuyama
Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol       Date:  1984

8.  Molecular staging of malignant melanoma: correlation with clinical outcome.

Authors:  S C Shivers; X Wang; W Li; E Joseph; J Messina; L F Glass; R DeConti; C W Cruse; C Berman; N A Fenske; G H Lyman; D S Reintgen
Journal:  JAMA       Date:  1998-10-28       Impact factor: 56.272

9.  Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes.

Authors:  A M Gown; A M Vogel; D Hoak; F Gough; M A McNutt
Journal:  Am J Pathol       Date:  1986-05       Impact factor: 4.307

10.  Molecular characterization of the melanocyte lineage-specific antigen gp100.

Authors:  G J Adema; A J de Boer; A M Vogel; W A Loenen; C G Figdor
Journal:  J Biol Chem       Date:  1994-08-05       Impact factor: 5.157

View more
  12 in total

Review 1.  Melanotic oncocytic metaplasia of the nasopharynx: a case report with a focus on immunohistochemical analyses and literature review.

Authors:  Shogo Tajima; Aki Ohkubo; Matsumi Yoshida; Kenji Koda; Ichirota Nameki
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

2.  HYPERsol: High-Quality Data from Archival FFPE Tissue for Clinical Proteomics.

Authors:  Dylan M Marchione; Ilyana Ilieva; Kyle Devins; Danielle Sharpe; Darryl J Pappin; Benjamin A Garcia; John P Wilson; John B Wojcik
Journal:  J Proteome Res       Date:  2020-01-14       Impact factor: 4.466

3.  Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype.

Authors:  Diane R Bielenberg; Yasuhiro Hida; Akio Shimizu; Arja Kaipainen; Michael Kreuter; Caroline Choi Kim; Michael Klagsbrun
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

4.  Parkinson's disease-related protein, alpha-synuclein, in malignant melanoma.

Authors:  Yasuhiro Matsuo; Tetsu Kamitani
Journal:  PLoS One       Date:  2010-05-05       Impact factor: 3.240

5.  Marginal and joint distributions of S100, HMB-45, and Melan-A across a large series of cutaneous melanomas.

Authors:  Hollis Viray; William R Bradley; Kurt A Schalper; David L Rimm; Bonnie E Gould Rothberg
Journal:  Arch Pathol Lab Med       Date:  2013-08       Impact factor: 5.534

Review 6.  Diagnostic and prognostic biomarkers in melanoma.

Authors:  David Weinstein; Jennifer Leininger; Carl Hamby; Bijan Safai
Journal:  J Clin Aesthet Dermatol       Date:  2014-06

7.  Cathepsin K in the immunohistochemical diagnosis of melanocytic lesions.

Authors:  Qiu Rao; Yan Wang; Qiu-Yuan Xia; Shan-Shan Shi; Qin Shen; Pin Tu; Qun-Li Shi; Xiao-Jun Zhou; Bo Wu
Journal:  Int J Clin Exp Pathol       Date:  2014-02-15

8.  Generation of metastatic melanoma specific antibodies by affinity purification.

Authors:  Birgit Schütz; Anita Koppensteiner; David Schörghofer; Katharina Kinslechner; Gerald Timelthaler; Robert Eferl; Markus Hengstschläger; Albert Missbichler; Harald Hundsberger; Mario Mikula
Journal:  Sci Rep       Date:  2016-11-17       Impact factor: 4.379

Review 9.  Current Molecular Markers of Melanoma and Treatment Targets.

Authors:  Kevin Yang; Allen S W Oak; Radomir M Slominski; Anna A Brożyna; Andrzej T Slominski
Journal:  Int J Mol Sci       Date:  2020-05-16       Impact factor: 5.923

Review 10.  Parkinson's Disease and Melanoma: Co-Occurrence and Mechanisms.

Authors:  Anindita Bose; Gregory A Petsko; David Eliezer
Journal:  J Parkinsons Dis       Date:  2018       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.